報價延遲最少15分鐘:2026/03/10 00:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
376.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
14.23/22.72
|
|
企業價值
249.21B
|
| 資產負債 |
|
每股賬面淨值
16.06
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
36.75B
|
|
每股收益
49.78
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio. |
